For benign brainstem tumors, the identification of BRAF alterations permits to use new anti –BRAF drugs such as dabrafenid or vemurafenid or anti—MEK as trametinib or selumetinib. This evidence concerns the gene BRAF and benign neoplasm of brain stem.